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ABSTRACT 
 
Malignant mesothelioma remains an incurable cancer. We demonstrated that mesotheliomas 
expressed EGFR (79.2%), ErbB4 (49.0%) and HER2 (6.3%), but lacked ErbB3. At least one 
ErbB family member was expressed in 88% of tumors. To exploit ErbB dysregulation in this 
disease, patient T-cells were engineered by retroviral transduction to express a panErbB-
targeted chimeric antigen receptor (CAR), co-expressed with a chimeric cytokine receptor 
that allows interleukin (IL)-4 mediated CAR T-cell proliferation. This combination is 
referred to as T4 immunotherapy. T-cells from mesothelioma patients were uniformly 
amenable to T4 genetic modification and expansion/ enrichment thereafter using IL-4. 
Patient-derived T4+ T-cells were activated upon contact with a panel of four mesothelioma 
cell lines, leading to cytotoxicity and cytokine release in all cases. Adoptive transfer of T4 
immunotherapy to SCID Beige mice with an established bioluminescent LO68 mesothelioma 
xenograft was followed by regression or eradication of disease in all animals. Despite the 
established ability of T4 immunotherapy to elicit cytokine release syndrome in SCID Beige 
mice, therapy was very well tolerated. These findings provide a strong rationale for the 
clinical evaluation of intracavitary T4 immunotherapy to treat mesothelioma. 
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Abbreviations 
BLI – bioluminescence imaging; CAR – chimeric antigen receptor; EGFR – epidermal 
growth factor receptor; ffLuc – firefly luciferase; IL – interleukin; i.p. - intraperitoneal; MPM 
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– malignant pleural mesothelioma; PSMA – prostate-specific membrane antigen; p/s – 
photons per second; RFP – red fluorescence protein; UT - untransduced  
 
1. Introduction 
 
Malignant mesothelioma is a locally aggressive tumor that is primarily attributable to 
inhalation of asbestos fibers [1], prompting stringent regulation of this mineral in many 
territories. Nonetheless, incidence continues to increase in many countries, reflecting the long 
latency period of disease progression [2]. Mesothelioma remains incurable with a median 
survival of 9 to 17 months [3, 4].  
Immunotherapy has long been posited as a logical approach to treat mesothelioma [5]. 
Promising data have emerged from clinical trials of immune checkpoint blockade in this 
disease [6]. In parallel, there has been increasing interest in the development of adoptive 
immunotherapeutic approaches using genetically engineered T-cells. Chimeric antigen 
receptors (CARs) are bespoke fusion molecules that couple an antigen recognition element to 
a tailored signaling domain, thereby enabling the HLA independent retargeting of T-cell 
specificity [7]. Interest has been fueled by the repeated demonstration of unprecedented 
therapeutic efficacy when autologous CD19 targeted CAR T-cells are administered to 
patients with refractory acute lymphoblastic leukemia [8]. The most successful CAR 
configurations employ a second generation design in which CD28 or 4-1BB costimulatory 
modules are fused to CD3][9-11]. While initial experience in patients with solid tumors has 
been disappointing, mesothelioma may represent a special case since tumors are amenable to 
regional CAR T-cell delivery to the affected body cavity. Preclinical data have provided 
strong support for this approach using CAR T-cells retargeted against mesothelin [12, 13] 
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and fibroblast activation protein [14, 15]. Clinical trials employing both intra-pleural [16, 17] 
and systemic delivery [18] are ongoing. 
An increasing concern with CAR T-cell immunotherapy is the emergence of 
therapeutic resistance due to target loss [19, 20]. This highlights the desirability of selecting 
multiple targets that contribute to disease pathogenesis and thus are subject to selective 
pressure for retention by tumors. In mesothelioma, the extended ErbB receptor family 
represents an attractive candidate to meet these requirements. Epidermal growth factor 
receptor (EGFR; ErbB1) is upregulated and phosphorylated in the majority of cases, 
compared to normal pleura [21-27]. Disappointingly however, clinical evaluation of EGFR 
tyrosine kinase inhibitors has proven ineffective in this disease [24, 25], while trials involving 
EGFR inhibitory antibodies are ongoing (www.clinicaltrials.gov, accessed February 5th, 
2017). Co-expression of HER2 (ErbB2) [24, 28] has also been reported, although ErbB3 and 
ErbB4 have not previously been evaluated. 
To redirect T-cell specificity against the ErbB family, we have engineered a second 
generation CAR named T1E28z. T1E28z engages 8 of 9 possible ErbB homo and 
heterodimers [29] and enables T-cells to elicit antitumor activity in preclinical models of 
ovarian, breast and head and neck cancers [29-31]. The CAR is co-expressed with a chimeric 
cytokine receptor named 4DE that delivers an interleukin (IL)-2/IL-15 signal upon binding of 
IL-4, thereby enabling the selective enrichment of CAR T-cells during ex vivo expansion 
[32]. Importantly, culture of the resulting ‘T4+’ T-cells in IL-4 does not alter their 
differentiation and maintains type 1 polarity [32]. T4 immunotherapy is currently undergoing 
Phase 1 evaluation by intra-tumoral delivery in patients with head and neck cancer [33]. This 
approach has a further theoretical advantage in mesothelioma treatment since IL-4 is 
commonly found in the tumor microenvironment, providing an additional source of 
stimulation for T4+ T-cells [34].  Here, we tested the hypothesis that T4+ T-cells derived from 
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patients with mesothelioma would exert meaningful antitumor activity against mesothelioma, 
justifying the clinical evaluation of this approach.  
 
2. Materials and methods 
 
Additional details are provided as an online supplement. 
 
2.1 Preparation of tissue microarray slides and immunohistochemistry of tumors 
Mesothelioma tissue microarrays (TMAs) were acquired from the Departmental 
Tissue Bank. Sections (3μm) were cut from formalin fixed paraffin-embedded TMA blocks 
of 168 mesotheliomas obtained at a surgical biopsy procedure (either video-associated 
thoracoscopic surgery or open pleural biopsy), and were prepared on appropriately coated 
slides. 
  Access to patient tissue samples and data is regulated under the Human Tissue Act 
and Guy’s and St Thomas’ Hospital Thoracic Cancer Biobank Access Committee (License 
number 12121) in accordance with NHS Research Ethics Committee conditions. 
After overnight incubation, the slides were dewaxed and endogenous peroxidase was 
blocked by treatment with 3% hydrogen peroxide for 30 min. Antigen was retrieved by 
microwaving slides in citrate buffer pH 6.0 for 3 x 4 minutes. Primary antibodies (all Abcam, 
Cambridge, UK) were rabbit polyclonal anti-EGFR (ab2430; 1:100), rabbit monoclonal anti-
ErbB2 (ab134182; 1:200), rabbit monoclonal anti-ErbB3 (ab93739; 1:200) and mouse 
monoclonal anti-ErbB4 (ab19391; 1:20). Each was applied for 60 min in humidified 
chambers at room temperature, and staining was performed with the avidin-biotin complex 
by using the VECTASTAIN ABC Elite kit (PK-6200, Vector Laboratories, CA). 3,3-
Diaminobenzidine (DAB) was used as a chromogen (Vector Laboratories, CA). Slides were 
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lightly counterstained with hematoxylin. Breast carcinoma sections were used as positive and 
negative controls for EGFR, HER2 and ErbB3. A pellet of A431 cells was used as positive 
control for ErbB4. For all negative controls, normal horse serum was used instead of primary 
antibody. Following staining, TMA slides were scored for intensity of staining by an 
independent histopathologist, who reported results as negative (absence of staining), low 
intensity (+), moderate intensity (++) or high intensity (+++).  
 
2.2 Genetic modification of patient T-cells 
           This study was approved by the Leeds West Research Ethics Committee 
(reference 12/YH/0392). Recombinant DNA constructs were expressed using the 
SFG retroviral vector. Retroviral transduction [35] and expansion of CAR T-cells 
using IL-4 was carried out as described [32]. 
 
2.3 Cytotoxicity and cytokine release assays 
           Monolayers of mesothelioma cell lines were incubated with 1x106 T-cells overnight, 
(effector:target ratio of 1:1). Cytokine measurements were performed by ELISA. Tumor cell 
viability was assessed by MTT assay. 
 
2.4 Animal studies 
           Experimentation complied with UK Home Office project license 70/7794. SCID 
Beige mice were inoculated by intraperitoneal (i.p.) injection with 2x106 retrovirus-
transduced LO68 tumor cells that co-express firefly luciferase (ffLuc) and red fluorescent 
protein (RFP) and were flow sorted to homogeneity. Tumor engraftment was confirmed by 
bioluminescence imaging (BLI) using the IVIS Spectrum Imaging platform and Living 
Image software (PerkinElmer, Waltham, MA, USA). Mice were sorted into groups based on 
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similar mean total flux. Patient-derived CAR T-cells were administered i.p. and tumor status 
monitored by BLI [36]. Mice were culled if symptomatic, or when experimental endpoints 
had been met. For statistical comparison of two groups, datasets were analyzed by Student’s 
t test. 
 
3. RESULTS 
 
3.1 Expression of ErbB receptors by malignant pleural mesotheliomas 
Tissue microarrays were prepared from 168 malignant pleural mesotheliomas (MPM). 
Histologic subtype was defined in 103 cases as epithelioid (56.7%), sarcomatoid (20.4%) or 
biphasic (22.8%). As expected [37], survival was significantly longer for patients with 
epithelioid mesotheliomas, compared to other subtypes (Fig. 1A).  
Immunohistochemical analysis (Table I and Fig. 1B) demonstrated that most tumors 
expressed EGFR, while ErbB4 was detected in half of cases. By contrast, HER2 expression 
was infrequent and ErbB3 was uniformly absent. At least one ErbB family member was 
expressed in 88% of tumors. ErbB receptor expression was strongly dependent upon 
histologic subtype, with highest expression in epithelioid tumors (Table I). Receptor 
distribution was mainly cytoplasmic (Supplementary Fig. S1).  
Univariate analysis indicated that median patient survival was significantly influenced 
by EGFR expression status, but not by that of other ErbB family members (Fig. 1C). Survival 
was shortest when tumors either lacked EGFR, or were strongly positive for EGFR 
expression (Fig. 1C and Table II). Similar findings were observed when analysis was 
restricted to tumors for which histologic subtype data were available (Table II and Fig. 1D). 
When restricted to epithelioid tumors, effect of EGFR expression on survival was no longer 
statistically significant (Supplementary Fig. 2). Nonetheless, similar trends towards lower 
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median survival were apparent when tumors either lacked EGFR or expressed EGFR at high 
levels (Table II). 
Multivariate analysis was undertaken to explore the interactive effects of EGFR and 
histologic status on patient survival. This demonstrated that histology remained a highly 
significant predictor of patient outcome. By contrast EGFR status was not a significant 
covariate, unless the analysis was restricted to the small number of tumors in which the 
highest level of EGFR positive was detected (Table III).  
 
3.2 CAR engineering of T-cells from mesothelioma patients  
Given the prevalent expression of ErbB receptors in mesotheliomas, we explored 
feasibility of generation of T4+ T-cells using peripheral blood from mesothelioma patients. 
All were male, aged 69.9+7.3 years (mean + SD) and had tumors of epithelioid (n=8), 
biphasic (n=2) or unspecified subtypes (n=2), at clinical stage T2N0 (n=6), T3N0 (n=5) or 
T4N2 (n=1). Blood was obtained prior to diagnostic surgery (n=10) or following 
chemotherapy (n=2). Control T-cells were transduced with SFG P4, which encodes for 4DE 
and P28z [35]. P28z binds to PSMA, which is not expressed in mesothelioma.  
Transduced CAR T-cells were selectively enriched by expansion in IL-4. Fig. 2 
demonstrates that gene transfer and IL-4 mediated ex vivo enrichment of CAR T-cells was 
achieved in all cultures (representative example, Fig. 2A; pooled data, Fig. 2B-D). Total cell 
number increased by 28.1+13.9 fold, accompanied by IL-4 mediated enrichment of T4+ T-
cells by 4.7+4.8 fold (mean + SD). 
 
3.3 In vitro assessment of antitumor activity of ErbB retargeted T-cells 
Co-cultivation assays were performed in which patient derived CAR T-cells were 
incubated with a panel of mesothelioma cell lines (REN, JU77, LO68 and H28). Tumor cell 
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lines expressed EGFR (Fig. 3A), HER2 (Fig. 3B) and ErbB4 (Fig. 3D), while low level 
expression of ErbB3 was detected in two cases (Fig. 3C). All four mesothelioma cell lines 
were destroyed by T4+, but not by control P4+ or untransduced T-cells (Fig. 4). Activation of 
T4+ T-cells was indicated by release of significantly elevated amounts of IL-2 (Fig. 5A) and 
IFN-J (Fig. 5B). 
 
3.4 In vivo assessment of patient derived ErbB retargeted CAR T-cells – single dose study 
An i.p. xenograft model was established in SCID Beige mice using ffLuc/RFP-
expressing LO68 cells. This approach was selected for three reasons. First, tumor progression 
models the propensity of mesothelioma to undergo intracavitary spread at a location in which 
human mesotheliomas also occur. Second, this model allowed us to examine the therapeutic 
activity and safety of patient derived T4+ T-cells, when delivered using a route that can cause 
cytokine release syndrome (CRS) [31]. Finally, i.p. delivery of tumor and T-cells is less 
traumatic to animals than intrapleural delivery. 
Inoculation of either 0.5 or 2 million ffLuc+ LO68 tumor cells led to engraftment 
followed by exponential tumor growth after 14 days (Supplementary Fig. S3). The higher 
tumor cell dose was selected for further studies. To examine in vivo antitumor activity, 40mL 
blood was obtained from a patient with epithelioid MPM (patient 31). T-cells were 
transduced with SFG T4 or the control SFG P4 vector and were expanded and enriched by 
culture in IL-4. The selective ability of this batch of T4+ CAR T-cells to kill LO68 tumor 
cells was confirmed (Supplementary Fig. S4A) prior to their adoptive transfer to animals 
bearing a 14 day established LO68 tumor xenograft. Fig. 6A demonstrates that T4+ patient T-
cells cause a transient regression of tumor burden. By contrast, P4+ T-cells exerted no 
therapeutic effect when compared to PBS. Treatment was extremely well tolerated with no 
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evidence of weight loss or other “soft” clinical indicators of CRS, such as ruffled fur, 
hunched posture or reduced mobility or grooming (Fig. 6B). 
 
3.5 Repeated administration of patient-derived ErbB re-targeted CAR T-cells exerts superior 
therapeutic activity 
We have recently shown that CAR T-cells are rapidly cleared from SCID Beige mice 
following i.p. delivery [38]. This contrasts to NSG mice where sustained engraftment leads to 
xenogeneic graft versus host disease (unpublished data). Consequently, we next explored the 
therapeutic efficacy and safety of repeated CAR T-cell dosing in the SCID Beige model. A 
40mL blood sample was obtained from a patient with epithelioid MPM (patient 36) and CAR 
T-cells were engineered and expanded as above. Antitumor activity of T4+ but not control T-
cells was confirmed using LO68 tumor cells (Supplementary Fig. 4B). CAR T-cells were 
adoptively transferred into tumor-bearing mice on days 14 and 21. Fig. 7A-B demonstrates 
that tumor regression was achieved in all T4+ T-cell treated mice, with disease eradication in 
2 of 5 cases. No weight loss was observed in any mouse (Fig. 7C). 
 
4. Discussion 
 
Solid tumors impose considerable obstacles to effective CAR T-cell immunotherapy. 
The first hurdle is the delivery of sufficient numbers of T-cells to the site of disease. While 
disseminated metastasis represents the main therapeutic challenge imposed by most cancers, 
some tumors primarily advance by loco-regional dissemination. This scenario provides a 
unique opportunity for CAR T-cell immunotherapy since direct administration of T-cells to 
such lesions obviates their homing requirement from the bloodstream. Furthermore, pre-
clinical studies demonstrate that regional CAR T-cell administration has a highly favorable 
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safety profile [31], with limited systemic absorption [39]. We have exploited this principle to 
initiate a clinical trial in which ErbB retargeted CAR T-cells are administered using the intra-
tumoral route in patients with head and neck cancer [33]. To date, no dose limiting toxicities 
or evidence of systemic absorption of CAR T-cells has been observed in the first ten treated 
patients. Here, we demonstrate preclinical proof of concept for the utility of a related 
approach to treat mesothelioma. Mesothelioma is highly suited to intra-cavitary delivery 
since tumors are directly accessible using a pleural or peritoneal catheter [12, 16, 40]. 
 We first profiled ErbB receptor expression in a large tumor series. The majority of 
MPM expressed EGFR, in agreement with previous reports [21-27]. Expression of EGFR has 
previously been linked to no alteration [21, 23, 25] or to improved survival of mesothelioma 
patients on univariate analysis [22, 27]. In agreement, we found that lack of EGFR was 
associated with shortened patient survival. Since this effect lost significance when the 
analysis was restricted to epithelioid tumors, it may in part reflect the tendency of poorer 
prognosis mesothelioma subtypes (notably sarcomatoid tumors) [41] to lack EGFR 
expression. Notably however, we also observed that in EGFR positive tumors, highest level 
expression was also linked to shortened survival. Although not been described previously, a 
similar trend was seen in a smaller study in which intensity of EGFR expression by 
mesotheliomas was ranked [21]. 
Expression of HER2 has previously been examined in mesothelioma, with divergent 
findings. Our finding that HER2 is infrequently detectable using immunohistochemistry is 
consistent with Garland et al. [24], but not with an earlier report in which 97% of tumors 
were positive [28]. In interpreting these findings, differing sensitivities of distinct 
immunohistochemical approaches should be considered.  
We also undertook an evaluation of ErbB3 and ErbB4 expression by MPM, building 
on earlier studies using immortalized cell lines [42-44]. While ErbB3 was not detected, about 
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half of tumors expressed ErbB4. Once again, the limited sensitivity of immunohistochemistry 
should be considered in interpreting these findings. Nonetheless, these data indicate that 
several ErbB dimer species recognized by the T1E28z CAR are present in most 
mesotheliomas, notably epithelioid tumors. 
 Immunotherapy using CAR T-cells generally involves the use of an autologous 
product. Consequently, it was imperative to demonstrate feasibility of transduction and 
expansion of patient-derived CAR T-cell products. To facilitate this, T1E28z was co-
expressed with the 4DE chimeric cytokine receptor which allows selective enrichment of 
CAR T-cells by culture in IL-4 [32]. This approach yields up to 8 billion CAR T-cells within 
2 weeks from 120mL blood, obtained from patients with advanced head and neck cancer 
(unpublished data). We show here that successful transduction and enrichment of CAR T-
cells was achieved in all patients, either at diagnosis or following chemotherapy. 
Functionality of the expanded cells was indicated by their ability to kill four mesothelioma 
cell lines, with release of IL-2 and IFN-J at significantly higher levels that control CAR T-
cells (due to density of plating and alloreactivity). Furthermore, we obtained sufficient CAR 
T-cells from 40mL patient blood to treat 10 mice bearing an established mesothelioma 
xenograft. A single cycle of treatment with T4+, but not control CAR T-cells led to transient 
tumor regression in all mice. Tumor response could be consolidated by the administration of 
a second CAR T-cell dose, causing disease eradication in 40% of animals. Notably, we have 
previously demonstrated that i.p. administration of T4+ T-cells to SCID Beige mice causes 
dose-dependent CRS. This results from the ability of human CAR T-cells to activate mouse 
macrophages, leading to IL-6 release [31]. Reassuringly however, no such toxicity was 
evident at the doses of CAR T-cells used here. 
 In conclusion, we have demonstrated ErbB receptor expression in most 
mesotheliomas, particularly of the epithelioid subtype. Exploiting this, human ErbB-
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retargeted CAR T-cells exert meaningful antitumor activity against mesothelioma cell lines 
and xenografts, without toxicity. These data provide strong support for the clinical evaluation 
of intracavitary T4 immunotherapy in patients with mesothelioma. 
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8. Figure legends 
 
Fig. 1 Histology, ErbB receptor expression and survival analysis of patients with malignant 
pleural mesothelioma. (A) Kaplan Meier plot of survival of patients with mesotheliomas of 
the specified histologic subtypes. (B) Frequency and level of expression of indicated ErbB 
family members in tissue microarrays derived from 168 mesotheliomas. All tumors were 
negative for ErbB3. (C) Kaplan Meier plots of survival of patients with mesothelioma 
according to frequency and level of expression of ErbB family members. Data shown in B 
and C includes all tumors in which histologic subtype was either defined or not specified. (D) 
Re-analysis of plots shown in C but restricted to patients with mesothelioma of defined 
histologic subtype. p values were generated by Log-rank (Mantel Cox) test. 
 
Fig. 2 Transduction efficiency and in vitro expansion of CAR T-cells from patients with 
malignant pleural mesothelioma. (A) Representative example in which patient-derived 
peripheral blood T-cells were transduced with the SFG T4 retroviral vector, which encodes 
for the ErbB-specific T1E28z CAR and 4DE chimeric cytokine receptor. After gene transfer, 
IL-4 was provided as sole cytokine support during the expansion phase. Pooled data indicate 
IL-4-mediated enrichment of T4+ CAR T-cells within the culture (B), numerical expansion of 
T-cells (C) or of T4+ T-cells (D). Data are derived from 12 separate patients comparing day 3 
and day 15 after transduction. 
 
Fig. 3 ErbB receptor expression by malignant pleural mesothelioma cell lines. The indicated 
cell lines were analyzed by flow cytometry for (A) EGFr (ErbB1); (B) HER2 (ErbB2); (C) 
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ErbB3 and (D) ErbB4, making comparison with an isotype control for monoclonal antibody 
staining (A-C) or conjugated secondary antibody alone for polyclonal antiserum (D). 
 
Fig. 4  In vitro cytotoxic activity of patient-derived ErbB re-targeted CAR T-cells against 
malignant pleural mesothelioma cell lines. CAR+ (T4 or control P4) or untransduced (UT) T-
cells were generated from 12 mesothelioma patients and were established in co-culture with 
the indicated tumor cell lines at a 1:1 ratio overnight. After removal of T-cells, residual viable 
tumor was quantified by MTT assay, making comparison with a parallel culture of tumor 
cells alone (“tumor” – set to 100%). Data show mean + SD of n=12 assays from individual 
donors. **** p<0.0001 comparing T4 with all other conditions by Tukey’s multiple 
comparisons test. 
 
Fig. 5 Cytokine release by patient-derived ErbB re-targeted CAR T-cells when co-cultivated 
with malignant pleural mesothelioma cell lines. Co-cultures were established between CAR+ 
(T4 or control P4) or untransduced (Untrans.) T-cells and the indicated tumor cell lines at a 
1:1 ratio overnight. Supernatants were collected and analyzed by ELISA for IL-2 (A) or IFN-
J (B). Data show mean + SD of triplicate samples from each patient-derived T-cell culture. 
ND – not done. 
 
Fig. 6  In vivo anti-tumor activity of T4 immunotherapy – single dose study. SCID Beige 
mice were injected on day 0 with 2 million ffLuc/RFP+ LO68 mesothelioma cells using the 
i.p. route. In parallel, an ErbB re-targeted (T4+) or control (P4+) CAR T-cell product was 
generated from a patient with epithelioid mesothelioma (patient 31) by retroviral transduction 
and expansion of the cells using IL-4. CAR T-cells (10 million) were administered by i.p. 
injection on day 14 (arrowed). Serial bioluminescence imaging (A) and weight measurement 
 19 
(B) was performed thereafter, making comparison with PBS treated control mice (mean + 
SD, n=5 mice per group). ***p =0.0003 (T4 v P4) and 0.0001 (T4 v PBS).  
 
Fig. 7  In vivo anti-tumor activity of T4 immunotherapy – repeated dose study. SCID Beige 
mice were injected on day 0 with 2 million ffLuc/RFP+ LO68 mesothelioma cells using the 
i.p. route. In parallel, an ErbB re-targeted (T4+) or control (P4+) CAR T-cell product was 
generated from a patient with epithelioid mesothelioma (patient 36) by retroviral transduction 
and expansion of the cells using IL-4. CAR T-cells or PBS were administered by i.p. 
injection at the arrowed time points on day 14 (10 million T-cells) and on day 21 (5 million 
T-cells). Serial bioluminescence imaging was performed on individual mice. Total flux 
(photons per second – A) and images of the animals are shown at each time point (B). Serial 
weight measurements were performed throughput (C). Data show mean + SD, n=5 (T4 / 
PBS) or 4 (P4) mice per group. For T4 v PBS, p= 0.02 (day 21); 0.0006 (day 35) and 0.05 
(day 42). For T4 v P4, p=0.06 (day 42) and 0.006 (day 49). 
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Tables 
 
 
 
 
Table I ErbB receptor expression by malignant pleural mesotheliomas 
 
  
EGFr 
 
 
HER2 
 
ErbB3 
 
ErbB4 
 
All tumors 
 
126 (79.2%)* 
 
9 (6.3%) 
 
0 (0%) 
 
70 (49.0%) 
 
Defined histologic subtypes 
 
 Epithelioid 
 
57 (89.1%) 
 
5(8.8%) 
 
0 (0%) 
 
31 (62.0%) 
 Sarcomatoid 6 (28.6%) 0 (0%) 0 (0%) 9 (34.6%) 
 Biphasic 
 
11 (61.1%) 1 (6.3%) 0 (0%) 8 (40.0%) 
* number of cases (percentage shown in brackets). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table(s)
 
 
Table II Median survival of patients with malignant pleural mesotheliomas 
 
  
Negative 
 
 
Low 
 
Moderate 
 
High 
All tumors     
 
 EGFr 
 
5.21 (28)* 
 
11.0 (58) 
 
11.7 (32) 
 
6.1 (10) 
 HER2 9.07 (116) 11.1 (9) NA (0) NA (0) 
 ErbB4 7.98 (67) 7.17 (58) 9.96 (4) NA (0) 
 
Defined histologic subtypes 
 
 EGFr 
 
4.99 (27) 
 
8.6 (34) 
 
11.3 (23) 
 
5.5 (5) 
 HER2 7.82 (76) 14.05 (6) NA (0) NA (0) 
 ErbB4 
 
7.00 (44) 5.45 (39) 9.96 (4) NA (0) 
Epithelioid subtype 
 
   
 EGFr 
 
7.00 (6) 11.38 (22) 11.7 (21) 6.74 (3) 
*Median survival in months (number of patients shown in brackets). NA – not applicable. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
          
          
 
Table III Multivariate analysis of prognostic factors for patient survival  
        
          
  
Coefficient (bi)* 
 
 
Hazard ratio [exp(bi)] 
 
95% CI 
 
p-value 
Histology 0.712 2.037 1.402-2.96 <0.001 
EGFR 0.263 1.0301 0.945-1.79 0.106 
     
Histology 0.572 1.772 1.263-2.485 0.001 
EGFR (High) 1.052 2.865 1.078-7.610 0.035 
*Cox proportional hazards model 
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